GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that […]
Readers respond: Expand access to obesity medicine
A recent Oregonian/OregonLive article highlights an important step toward improving access to safe, effective GLP-1 medications, (“Ozempic and Wegovy will be sold for half price at Costco,” Oct. 8).
Observation of unique stable nano-assemblies of a lipidated glucagon-like peptide 1 analogue
Soft Matter, 2025, Accepted ManuscriptDOI: 10.1039/D5SM00801H, Paper Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Eva Prada Brichtova, Ana L. Gomes Dos Santos, Sophie JacksonLipidation of glucagon-like peptide 1 (GLP-1) has been widely investigated and utilized as a strategy for the half-life extension of the drug in vivo. […]
The 2 factors driving your health care costs higher and higher
Health insurance premiums for 2026 are on the rise. It’s that time of year again: open enrollment. With it comes a lot of questions: Do I go with an HMO or a PPO? Do I need an FSA or an HSA? What’s my deductible again? It’s very confusing, but one thing is clear: The cost […]
Ultra Long-Acting GLP-1 May Offer Benefits Over Others
As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing. Medscape Medical News
Diageo has a great new CEO: is this the start of a share price rally?
Diageoâs (LSE: DGE) share price jumped 5% yesterday (10 November). The driver of the gain was news that the company has a new CEO. Could this be the start of a long-overdue share price rally? Letâs discuss. A top choice for CEO Diageo has appointed Dave Lewis as its new CEO. And the market is […]
GLP-1 Agonists Linked to Anorgasmia in a 71-Year-Old Woman
Clinicians prescribing GLP-1 agents should ask about sexual function and consider medication review if new anorgasmia appears. Medscape UK
GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes
In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.
Mark Cuban strongly reacts to major Medicare change
Originally a trade term, Most-Favored-Nation status aims to ensure equal treatment among trading partners. In medication pricing, its goal is that the U.S. will get the best deal available globally. Specifically, MFN prescription drug pricing ties cost in the U.S. to the lowest price paid by other wealthy nations — such as Canada, Germany, or […]
Eli Lilly cuts surprising deals with upstart biotech players
Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant obesity and diabetes franchises and enter cutting-edge […]